Precision Medicine Initiative (PMI) Committee Meeting

December 13, 2023

NIH NATIONAL CANCER INSTITUTE

Agenda –

- Role Call
- PMI Stakeholder Approach
- Project Status Updates
- HR Status/HER2 Status Requirements
- Cohort/Strata
- FFP Testing Approach
- STMF/CLIA/Path Form Review
- Project Discussion Items
- Next Steps

Stakeholder Representation



PMI Approach

PMI Approach: Moving Forward

Focus on PMI workflows, processes and implementation will shift to the Group's perspective.

- Groups do not feel like they were a part of the requirements/solutioning process for the PMI project.
- Requirements and workflows were not communicated out to the Groups in a streamlined process.
- Implementation decisions will be focused on the end users vs ONLY on the universal approach.

Data Science Stakeholder Engagement Model (DSSEM)

Identifying and establishing a proven methodology to stakeholder management has been critical to the success of development, adoption, and implementation of the NCI CTEP CDISC harmonized standards.



PMI Transition to use the DSSEM Methodology

1

Facilitate Lessons Learned Sessions

- Engage PMI Stakeholders
  - *NCTN Groups*
  - *PMI Project Team*
  - *Federal Leadership*

2

Report Summary of findings

- Review/discuss findings with Federal Leadership
- Present to PMI Committee as appropriate

3

Develop Action Plans

- Prioritize findings
- Initiate transition to DSSEM

4

Implement Action Plans

- Prepare impact analysis
- Create project roadmap

Transition Plan for PMI Stakeholder Engagement

Jan - Feb 2024

- Facilitate a series of lessons learned sessions with the PMI Stakeholders
  - *Focus: how to improve PMI processes, communication and workflows*
- Begin transition to DSSEM Methodology
- Develop PMI Communication Plan

March - April 2024

- Draft summary report of lessons learned findings
- Prioritize findings and develop action plans
- Complete transition to DSSEM Methodology
- Implement PMI Communication Plan

May 2024 and on

- Review lessons learned summary report with applicable PMI Stakeholders
- Verify needed action plans with Federal Leadership
- Implement action plans
- Create PMI Roadmap

Project Status Updates

Project Updates – PMI Deliverables

	Deliverable	Target Release Date	Target Release Vehicle
☑	**ComboMATCH changes** (Disease fields, histology, behavior field code)	**PROD Released: July 17, 2023**	**Screening Protocol EC Template v2.0**
☑	**Designated Labs for Combo**	**PROD Released: Sept 6, 2023**	**Screening Protocol EC Template v3.0** *(UAT Release w/EA – 07/27/2023)*
☑	**Re-Screening ComboMATCH**	**PROD Released: Sept 27, 2023**	**MSRP Re-Screening EC Template v1.0** *(UAT Release w/EA – 07/27/2023)*
☑	**Cohort Migration**	**PROD OPEN Released: Sept 28, 2023** **PROD EC Temp v1.0 Released: *Oct 27, 2023***	**Treatment Protocol Cohort Migration EC Template v1.0**
☑	**MyeloMATCH Tx Protocol Crossover** (for S01, CTG01 and EA02)	*n/a*	Part of the existing Treatment Protocol workflow; no PRODUCTION OPEN Release required; the Westat team is prepared to support this workflow as Groups begin using it.
☑	**Re-Screening MM**	**PROD RS EC Temp v2.0 Released: *Nov 30, 2023***	No PRODUCTION OPEN Release is required for MM Re-Screening activities; the Westat team is prepared to support this workflow as Groups begin using it. **MSRP Re-Screening EC Template v2.0** *(UAT Release w/SWOG – 10/6/2023; 2nd UAT Release w/SWOG – 10/24/2023; 3rd UAT Release to SWOG – 11/07/2023; PROD RS EC Template v2.0 target date 11/30/2023)*
☐	**MyeloMATCH Stratification**	*PROD OPEN Release: Dec 18, 2023*	Part of existing Treatment Protocol Workflow.
☐	**BETA PMI Screening Protocol ALS v2.0** *New Forms: STMF, CLIA, PATH GROUP*	*BETA Release: January 12, 2023*	Target date for BETA Release for Groups to initiate UAT activities. *(accompanied by BETA Screening Protocol Central Study ALS v2.0)*
☐	**PROD PMI Screening Protocol ALS v2.0** *New Forms: STMF, CLIA, PATH GROUP*	*PROD Release: March 5, 2024*	Target date for PRODUCTION Release for Groups to initiate implementation activities. *(accompanied by PROD Screening Protocol Central Study ALS v2.0)*

Project Updates - EC Template Release Schedule

Template	Version	UAT Release Date	PROD Release Date	Details
PMI Screening Protocol EC Template	V1.0	Released: 12/16/2022	**Released: 02/15/2023**	
PMI Screening Protocol EC Template	V2.0	Released: 05/01/2023	**Released: 07/17/2023**	Includes CM changes (Disease fields, histology, behavior field code)
PMI Screening Protocol EC Template	V3.0	Released: 07/27/2023	**Released: 09/06/2023**	Includes updates for Designated Labs (DLAP fields)
PMI Screening Protocol EC Template Fact Sheet	*v3.1*	*n/a*	*Released: 10/6/2023*	Administrative version/release of the Fact Sheet to capture MyeloMATCH Field Help/Instructional Text for the 'Prior therapy name' field; to be used in conjunction with the PMI Screening Protocol EC Template v3.0.
PMI Treatment Protocol EC Template	V1.0	Released: 12/16/2022	**Released: 02/15/2023**	
PMI Treatment Protocol EC Template Fact Sheet	*V1.1*	*n/a*	**Released:** *11/16/2023*	Administrative version/release of the Fact Sheet to provide a stand-alone TX Protocol-specific document allows Groups to easily access the Fact Sheet information; to be used in conjunction with the PMI Treatment Protocol EC Template v1.0.
PMI MSRP Re-Screening EC Template	V1.0	Released: 07/27/2023	**Released: 09/27/2023**	*Supports ComboMATCH MSRP.*
PMI MSRP Re-Screening EC Template	V2.0	Re-released: 11/07/2023 Re-released: 10/24/2023 Released: 10/06/2023	**Released**: **11/30/2023**	*Supports MyeloMATCH MSRP; PROD release date confirmed.*
PMI Treatment Protocol Cohort Migration EC Template	V1.0	Released: 09/18/2023	**Released: 10/27/2023**	Supports cohort migration activities for ComboMATCH.
PMI Treatment Protocol Cohort Migration EC Template Fact Sheet	*v1.1*	Re-Release*: 10/4/2023*	**Released***: 10/27/2023*	Administrative version/re-release of the UAT Fact Sheet to capture updated Field Help/Instructional Text for the 'Cohort migration assignment' field; to be used in conjunction with the UAT PMI Treatment Protocol Cohort Migration EC Template v1.0.

ComboMATCH Priority 1 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	Yes	11/29: No Updates 12/13 :No Updates
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	Yes	11/29: Released on 11/20. 12/13: No Updates
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	Yes	11/29: No Updates 12/13: No Updates
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	Yes	11/29: Protocol amendment was disapproved; waiting for protocol, OPEN/Rave build ready. 12/13: Protocol amendment resubmitted on Monday
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	Yes	11/29: Implementing ineligibility in MM - Should be ready to test for S3 in a few weeks. 12/13: No Updates

ComboMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Activated	Current Status
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Yes	11/29: No Update 12/13: No Update
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Yes	11/29: Activated on 11/15 12/13: No Update

ComboMATCH Priority 3 List

#	Protocol #	Protocol Title	Group	Current Status
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	**11/1: Dropped**
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	**11/29: Received confirmation will no longer be a CM Study, moving to a COG study.** **12/13:**
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	**11/29: Ready to begin testing; in combination with first cohort migration study. There will be a script to use; CTSU can begin creating patients.** **12/13: Almost complete with internal OPEN testing; contacting CTSU and Engineering for FFP Cohort Migration**
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	**11/29: Waiting on protocol** **12/13: Updated protocol submitted to CTEP on 12/4. Waiting to get test patients and working on the build.**

#	Protocol #	Protocol Title	Group	Current Status
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	**11/29: All done with testing through Step 4, testing ineligibility and almost ready to test by next week.** **12/13: Completed testing.**
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	**11/29: Programmer for randonode is working on ineligibility.** **12/13: Delay because study structure; removing step 2 enrollment so SWOG has to redo work before they can move forward.**
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	**11/29: Testing ineligibility workflow** **12/13: Testing in progress**
6	MM1OA-EA02	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	**11/29: Target to add this into OPEN around 12/5** **12/13: Working on getting rando files to start OPEN testing**

MyeloMATCH Priority 2 List

#	Protocol #	Protocol Title	Group	Current Status
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to Stem Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	**12/13:**
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	**12/13:**
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of targeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for Treatment of Higher Risk Myelodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	**12/13:**

PMI Project Discussion Items

HR Status and HER2 Status – Requirements

NEW option for capturing HR status:

- Hormone Receptor Status - Single element question that combines ER and PgR result details:
- The options the user could select from:
  - Unknown
  - ER+ and PgR+
  - ER+ and PgR (-)
  - ER (-) and PgR+
  - ER (-) and PgR(-)

- **NEW option for capturing HER2 Status details:**
- ***HER2 Status***
  - HER2 status IHC Score
    - The options the user could select from:
      - Unknown
      - 0
      - 1+
      - 2+
      - 3+
  - HER2 status FISH result
    - The options the user could select from:
      - Unknown
      - Positive
      - Negative
  - Copy Number value for FISH result (Help text: The number of copies of the gene (e.g. 10))
    - The options the user could select from:
      - Unknown
      - Text box- Allow user to type in a response for CN value

Cohort/Stratum Submission

- Based on feedback from Groups, we understand that not every group is collecting Cohort and Stratum the way we have designed for PMI.
- Moving forward, For MM Groups will not need to return the cohort/stratum information to MATCHBox.
- Impacts
  - Groups will be responsible for tracking/controlling accrual by cohort and stratum
  - PMI Project team is assessing impacts to
    - MATCHBox
    - RSS APP
    - RAVE/OPEN
    - Regulatory
    - BIOT x Data Science
    - Group Impacts

FFP Testing

- **What is FFP Testing:**
  - FFP Testing is the final step in ensuring a new Treatment Protocol is ready for activation prior to release in production. It involves coordination between several parties to take a test participant through a typical workflow.

- **What's Changing?**
  - If a group already has an active treatment protocol in the study, an enrolling site volunteer will not be used. Instead, Westat will do the enrollment to the screening study and the Treatment Protocol Group Representative will do the enrollment to the treatment protocol.

FFP Testing

- **Why Make This Change?**
  - To lower the burden on the Group, Westat, and Essex staff.
    - It is time-consuming to use an enrolling site volunteer. The Group has to identify the volunteer who then must then be trained by Westat on both the screening study and the treatment protocol. Because the volunteer is unlikely to have an account on the UAT environment where the testing is done, a new account must be set up for them.
    - Because the group is already experienced setting up a treatment protocol for the study, the likelihood of usable feedback from the enrolling site volunteer is small.
    - This change follows what is done for other trials; the level of testing required is reduced as the study matures. It is what the Groups would expect.
    - Delays in completing the FFP Test are eliminated because it is not dependent on the enrolling site volunteer's workload.

- **What's Not Changing?**
  - The Enrolling Site Volunteer will still be required for FFP Testing for the screening study and for any group's first treatment protocol to be activated on a study.

STMF/CLIA/Path Group Update

- **Update on forms and awareness**

Open Discussion

- Register patients when protocol is not open at the site
  - How we currently approach this workflow:
    - Neither CM or MM has no way of knowing which treatment protocols a site has open. If we want an automated solution to this
    - Only option is that the verification committee will confirm TA and get back sent to OPEN; then reach out to the CM help desk and request a new assignment. Not challenging for engineering team and bio team to get a new assignment and have another review with the verification committee. Site realizes they don't have it → opens a help desk ticket and then the verification process starts
- Register patients when protocol is not open, and patient is not eligible
  - Continue to register the patient, get the ineligible status back
  - Alliance: Original ineligible workflow is not ideal, patient may not have all the information upfront, don't normally register a patient that is not eligible. Could they go to the rescreening form to request a new match?
  - SWOG: Also prefers to go back to the rescreening form to request a new match. It is confusing for the site to figure out the three different pathways depending on situation vs if you need an assignment for any reason, always go back to the rescreening.
  - Project Team: How many steps are supported on the forms? Not sure how many times this could happen?
  - SWOG: Can there be an integrated Rave form….to include a request for a new assignment.
  - Project team: Issue with that approach, OPEN will not know the steps, gap where OPEN will not know what happened in Rave. Team will need to understand what the impact would be.

Open Discussion

- Create a new form in Rave that they need a new assignment so we don't have to go through OPEN.
- Rick: On the original MATCH, built in 4 possible iterations for screening registration. Only had 2 that attempted another treatment assignment. Would not be a heavy lift to add in 4 iterations on CM.
  - Another approach is to build in a return to trial functionality. Click on return to trial and they choose their path. MATCHbox needs to know the state and where they are in the process.
  - Project Team: Even though we had a patient enroll on a 2nd treatment arm, only went on the 2nd because of the 1st one.
- SWOG: Could we have something in OPEN to confirm what the site does? A question that is part of that step enrollment but when the assignment comes back, what would be their next assignment.

- Where is the most logical place for sites to go to for this scenario?
  - SWOG: Screening study is the most logical place to do this (which system does not matter)
  - Allison: agreed Screening study is a logical option
  - Rick: Rave is not where you go to do registration related activities; conducting via OPEN is probably the most logical place for end users at the sites and from a system perspective.

Next Steps

Next Steps

Next meeting will be on 1/10/2024 at 1:00pm EST

Agenda

- Role Call
- Project Status Update
- Group Status Update
- Rave Demo (Forms)
- Project Discussion Item

Communication

Contact the PMI Mailbox for any PMI related questions & comments

pmistandards@nih.gov

The project team will respond within 48 hours with a response or a follow up

PMI Wiki

https://wiki.nci.nih.gov/display/CDISC/Precision+Medicine+Initiative

All presentations, recordings, minutes, project documents and releases will be posted on this wiki

NATIONAL CANCER INSTITUTE

www.cancer.gov

www.cancer.gov/espanol

Appendix

Target Timeline

Nov – Mid Dec 2022

Group Activities
- Develop Study-specific Rave CRFs

NCI Activities
- ComboMATCH UAT Matchbox Environment
- MyeloMATCH UAT Matchbox Environment
- MATCHBox & OPEN Integrations for UAT
- Prepare Beta Screening & Treatment ALS files

Mid Dec 2022

NCI Activities
- Release EC Templatev1
- Release Beta Screening Protocol ALS
- Release Beta Treatment Protocol ALS
- aMOI List Approval and MATCHBox Upload

Mid Dec to Jan 30, 2023

Group Activities
- UAT Testing

NCI Activities
- Iterative updates to test findings (show-stoppers)

Target Timeline

Jan 31, 2023

NCI Activities
- Release EC Template v1
- Release Prod Screening Protocol ALS
- Release Prod Treatment Protocol ALS
- Release Prod Central Study ALS
- Release NCI OPEN Integrations for Prod
- Release NCI Genexus Installation (MyeloMATCH)

Jan 31 to Feb 14, 2023

NCI + Group Activities
- Support Group Study Builds

Feb 14, 2023

NCI + Group Activities
- Launch BOTH Initiatives

Spring 2023

NCI Activities
- Release Additional ALS(s)

ComboMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
1	EAY191	Molecular Analysis for Combination Therapy Choice (ComboMATCH)	ECOG-ACRIN	8/15/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	
2	EAY191-N4	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers A ComboMATCH Treatment Trial	NRG	8/15/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Olaparib (AZD2281) (747856) (O) Selumetinib (AZD6244 hydrogen sulfate) (748727)
3	EAY191-E4	A ComboMATCH Treatment Trial ComboMATCH Treatment Trial E4: Nilotinib and Paclitaxel in Patients with Prior Taxane-Treated Solid Tumors	ECOG-ACRIN	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Nilotinib (747599) (O) Paclitaxel (Taxol) (673089)
4	EAY191-N2	A ComboMATCH Treatment Trial EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients with Hormone Receptor-Positive Metastatic Breast Cancer with a Frameshift or Nonsense Mutation or Genomic Deletion in NF1	NRG	8/26/2022 Approval on Hold	Revision 3 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Binimetinib (788187) (O) Fulvestrant (Faslodex) (719276)
5	EAY191-S3	Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors	SWOG	8/29/2022 Approval on Hold	Revision 4 back from CIRB with approval. On hold for DTL, funding sheet and IND filing.	(P) Ipatasertib (781451) (O) Paclitaxel (Taxol) (673089)

ComboMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
6	EAY191-A6	A ComboMATCH Treatment Trial: FOLFOX in Combination with Binimetinib as 2nd Line Therapy for Patients with Advanced Biliary Tract Cancers with MAPK Pathway Alterations	Alliance	Approval on Hold 9/14/2022	Rev 4 approved by CIRB on 10/24. CTEP currently reviewing stips.	(P) Binimetinib (788187) (O) OXALIplatin (Eloxatin) (266046) (O) 5-Fluorouracil (5-FU) (19893) (O)Leucovorin calcium (3590)
7	EAY191-A3	Palbociclib and Binimetinib in RAS-Mutant Cancers	Alliance	Approval on Hold 8/26/2022	Rev 2 sent to CIRB . Reviewed on 10/6, study team responding to stips	(P) Palbociclib (PD-0332991) (772256) (O) Binimetinib (788187)

ComboMATCH Priority 3 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps	Primary Agent Name (P) Other Agent Name (O)
8	EAY191-A2	Olaparib Plus Low-Dose Alpelisib for Breast Cancer	Alliance	In Review 4/4/2022	Rev 3 recv;d 10/19, currently with LR. Looks like it'll be another disapproval. Not yet sent to CIRB for initial review.	(P) Olaparib (AZD2281) (747856) (O) Alpelisib (BYL719) (801658)
9	EAY191-C1	Phase 2 Subprotocol of the Combination of a MEK Inhibitor and a Pan-RAF Inhibitor in Patients with Relapsed/Refractory Tumors Harboring Activating MAPK Pathway Mutations	COG	In Review 9/29/2022	Protocol reviewed at PRC 10/20; CR is being put together	(P) Selumetinib (AZD6244 hydrogen sulfate) (748727) (O) DAY101 (TAK-580, MLN-2480) (800798)
10	EAY191-E5	ComboMATCH Treatment Trial E5: A Randomized Phase II Study of AMG 510 (Sotorasib) with or Without Panitumumab in Advanced Solid Tumors	ECOG-ACRIN	In Review 2/22/2022	Waiting for revision 2 since 9/28; reminder was sent to EA 10/24	(P) AMG 510 (Sotorasib) (825510) (O) Panitumumab (742319)
11	EAY191-N5	Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, A Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial	NRG	In Review 11/22/2021	Rev 3 disapproval sent 10/15; waiting for Rev 4	(P) Neratinib (783782) (O) Palbociclib (PD-0332991) (772256)

MyeloMATCH Priority 1 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
1	MYELOMATCH	Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials	SWOG	11/12/2021: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
2	MM1YA-S01	A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) to (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, and Azacitidine + Venetoclax in Patients Aged 59 or Younger with High-Risk (Adverse) Acute Myeloid Leukemia; A MYELOMATCH Clinical Trial	SWOG	9/2/2022: Approval on Hold	CIRB Reviewed on 9/15, version with stips under CTEP review now.
3	MM1YA-CTG01	A Measurable Residual Disease (MRD) Driven, Phase II Study of Venetoclax Plus Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk Acute Myeloid Leukemia: A Tier 1 MYELOMATCH Clinical Trial	CCTG	9/2/2022: Approval on Hold	CIRB Review Oct 6, responding to stips
6	MM1OA-EA02 (Concept)	A Randomized Phase II Study of HMA-Based Therapies for the Treatment of Older Adults with Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia: A myeloMATCH Treatment Trial	ECOG-ACRIN	8/29/2022: Approved, no protocol yet	Waiting for protocol

MyeloMATCH Priority 2 List

Study #	Document Number	Document Title	Group	Current Status	Next Steps
4	MM2YA-EA01	Eradicating Measurable Residual Disease in Patients with Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial	ECOG-ACRIN	1/21/2022: In Review	Reviewed by CIRB, responding to stips
5	MM1OA-S02	A Randomized Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor Cedazuridine-Decitabine (ASTX727) for the Treatment of Newly Diagnosed TP53-Mutated Acute Myeloid Leukemia in Older Patients: A myeloMATCH Treatment Trial	SWOG	10/17/2022: In Review	Scheduled for PRC 11/4
7	MM1MDS-EA03 (Concept	ERADICATE MDS with TP53 Study: Efficacy of taRgeted Agents Combinations with Oral DNMT1 Inhibitor C-DEC (ASTX727) for TrEatment of Higher Risk myElodysplastic Syndromes with TP53 Mutations: A Non-Comparative, Parallel, Multi-Arm Phase 2 Study	ECOG-ACRIN	8/12/2022: Approval on hold, waiting for drug commitment	W+A6:G8aiting for Astex commitment, Genentech has provided commitment on 10/20

Review Schemas

EAY191-N4


Protocol N4
EAY191-N4
People with:
• RAS Pathway Mutant (KRAS, NRAS, HRAS, NF1, BRAF)
• AND Ovarian (including primary peritoneal and fallopian tube) OR Endometrial Cancer
• Excludes:
◦ Prior MEK inhibitors
◦ Prior PARP inhibitors with disease progression (Prior PARP inhibitors are allowed if there was no disease progression)
Cohort 1
EAY191-N4.C1
People with Ovarian (including primary peritoneal and fallopian tube) Cancer
N = 85
Cohort 2
EAY191-N4.C2
People with Endometrial Cancer
N = 80
R
R
Treatment Regimen 1
EAY191-N4.C1.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C1.R2
(Selumetinib)
Participants on Treatment Regimen 2 that progress are eligible to crossover to Treatment Regimen 1 in the same Cohort
Treatment Regimen 1
EAY191-N4.C2.R1
(Selumetinib + Olaparib)
Treatment Regimen 2
EAY191-N4.C2.R2
(Selumetinib)
KEY
R
Randomization

EAY191-E4


Protocol E4
EAY191-E4
People with:
• Previous taxane therapy (metastatic setting)
• Excludes:
◦ Platinum-resistant epithelial serous ovarian cancer
◦ cKIT variants
◦ PDGFRA D842V variants
N = 40
Treatment Regimen 1
EAY191-E4.R1
(Nilotinib + Paclitaxel)

EAY191-N2- Draft



EAY191-S3


Protocol S3
EAY191-S3
People with:
• Advanced or metastatic non-breast solid tumors
• A mutation in AKT1/AKT2/AKT3
• Progressed on prior taxane therapy
Excludes:
• Mutations in KRAS, NRAS, HRAS or BRAF
• Prior AKT inhibitor
N = 33
Treatment Regimen 1
EAY191-S3.R1
(Paclitaxel + Ipatasertib)

MMIYA-CTG01 Draft